BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3161165)

  • 1. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease.
    Kuhl DE; Markham CH; Metter EJ; Riege WH; Phelps ME; Mazziotta JC
    Res Publ Assoc Res Nerv Ment Dis; 1985; 63():199-209. PubMed ID: 3161165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method.
    Kuhl DE; Metter EJ; Riege WH
    Ann Neurol; 1984 May; 15(5):419-24. PubMed ID: 6610384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral metabolism of glucose in benign hereditary chorea.
    Suchowersky O; Hayden MR; Martin WR; Stoessl AJ; Hildebrand AM; Pate BD
    Mov Disord; 1986; 1(1):33-44. PubMed ID: 2973557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.
    Kuhl DE; Metter EJ; Riege WH; Markham CH
    Ann Neurol; 1984; 15 Suppl():S119-25. PubMed ID: 6234856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.
    Kuhl DE; Phelps ME; Markham CH; Metter EJ; Riege WH; Winter J
    Ann Neurol; 1982 Nov; 12(5):425-34. PubMed ID: 6217782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.
    Mazziotta JC; Phelps ME; Pahl JJ; Huang SC; Baxter LR; Riege WH; Hoffman JM; Kuhl DE; Lanto AB; Wapenski JA
    N Engl J Med; 1987 Feb; 316(7):357-62. PubMed ID: 2949152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's, and Parkinson's diseases.
    Metter EJ; Riege WH; Kameyama M; Kuhl DE; Phelps ME
    J Cereb Blood Flow Metab; 1984 Dec; 4(4):500-6. PubMed ID: 6238975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison study of positron emission tomography, X-ray CT and MRI in parkinsonism with dementia].
    Okada J; Peppard R; Calne DB
    Nihon Igaku Hoshasen Gakkai Zasshi; 1989 May; 49(5):643-56. PubMed ID: 2798056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
    Juh R; Kim J; Moon D; Choe B; Suh T
    Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal caudate glucose metabolism in persons at risk for Huntington's disease.
    Young AB; Penney JB; Starosta-Rubinstein S; Markel D; Berent S; Rothley J; Betley A; Hichwa R
    Arch Neurol; 1987 Mar; 44(3):254-7. PubMed ID: 2950844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral mapping of apraxia in Alzheimer's disease by positron emission tomography.
    Foster NL; Chase TN; Patronas NJ; Gillespie MM; Fedio P
    Ann Neurol; 1986 Feb; 19(2):139-43. PubMed ID: 3485952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography in the early diagnosis of Huntington's disease.
    Hayden MR; Martin WR; Stoessl AJ; Clark C; Hollenberg S; Adam MJ; Ammann W; Harrop R; Rogers J; Ruth T
    Neurology; 1986 Jul; 36(7):888-94. PubMed ID: 2940474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.
    Harris GJ; Pearlson GD; Peyser CE; Aylward EH; Roberts J; Barta PE; Chase GA; Folstein SE
    Ann Neurol; 1992 Jan; 31(1):69-75. PubMed ID: 1531910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral glucose metabolism in the Lennox-Gastaut syndrome.
    Theodore WH; Rose D; Patronas N; Sato S; Holmes M; Bairamian D; Porter RJ; Di Chiro G; Larson S; Fishbein D
    Ann Neurol; 1987 Jan; 21(1):14-21. PubMed ID: 3103526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging local brain function with emission computed tomography.
    Kuhl DE
    Radiology; 1984 Mar; 150(3):625-31. PubMed ID: 6607481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.
    Leenders KL; Frackowiak RS; Quinn N; Marsden CD
    Mov Disord; 1986; 1(1):69-77. PubMed ID: 2973559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated brain iron is independent from atrophy in Huntington's Disease.
    Dumas EM; Versluis MJ; van den Bogaard SJ; van Osch MJ; Hart EP; van Roon-Mom WM; van Buchem MA; Webb AG; van der Grond J; Roos RA;
    Neuroimage; 2012 Jul; 61(3):558-64. PubMed ID: 22480728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortical abnormalities in Alzheimer's disease.
    Foster NL; Chase TN; Mansi L; Brooks R; Fedio P; Patronas NJ; Di Chiro G
    Ann Neurol; 1984 Dec; 16(6):649-54. PubMed ID: 6335378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.